Gilead Sciences, Inc. [GILD] stock is trading at $87.36, up 0.70%. An important factor to consider is whether the stock is rising or falling in short-term value. The GILD shares have gain 3.18% over the last week, with a monthly amount glided 4.14%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Gilead Sciences, Inc. [NASDAQ: GILD] stock has seen the most recent analyst activity on October 17, 2024, when Bernstein initiated its Outperform rating and assigned the stock a price target of $105. Previously, Wells Fargo upgraded its rating to Overweight on October 07, 2024, and elevated its price target to $100. On July 08, 2024, upgrade upgraded it’s rating to Outperform but maintained its price target of $93 on the stock. Maxim Group reiterated its Buy rating and decreased its price target to $85 on May 01, 2024. HSBC Securities upgraded its rating to a Hold but $69 remained the price target by the analyst firm on April 24, 2024. Truist downgraded its rating to Hold for this stock on February 22, 2024, and downed its price target to $82. In a note dated November 09, 2023, Deutsche Bank initiated an Hold rating and provided a target price of $75 on this stock.
Gilead Sciences, Inc. [GILD] stock has fluctuated between $62.07 and $87.86 over the past year. Currently, Wall Street analysts expect the stock to reach $80.45 within the next 12 months. Gilead Sciences, Inc. [NASDAQ: GILD] shares were valued at $87.36 at the most recent close of the market. An investor can expect a potential drop of -7.91% based on the average GILD price forecast.
Analyzing the GILD fundamentals
Gilead Sciences, Inc. [NASDAQ:GILD] reported sales of 27.78B for the trailing twelve months, which represents a growth of 5.46%. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at 0.36%, Pretax Profit Margin comes in at 0.06%, and Net Profit Margin reading is 0.04%. To continue investigating profitability, this company’s Return on Assets is posted at 0.02, Equity is 0.05 and Total Capital is 0.24. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.28.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 86.75 points at the first support level, and at 86.14 for the second support level. However, for the 1st resistance point, the stock is sitting at 87.81, and for the 2nd resistance point, it is at 88.26.
Ratios To Look Out For
For context, Gilead Sciences, Inc.’s Current Ratio is 1.14. On the other hand, the Quick Ratio is 0.95, and the Cash Ratio is 0.26. Considering the valuation of this stock, the price to sales ratio is 3.92, the price to book ratio is 5.95 and price to earnings (TTM) ratio is 106.77.
Transactions by insiders
Recent insider trading involved Parsey Merdad, Chief Medical Officer, that happened on Oct 01 ’24 when 2000.0 shares were sold. Officer, MERDAD V PARSEY completed a deal on Oct 01 ’24 to buy 2000.0 shares. Meanwhile, Chief Medical Officer Parsey Merdad sold 21246.0 shares on Sep 12 ’24.
